TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26066932

Group type: EXPERIMENTAL
Intervention: Gain-framed warnings
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Loss-framed warnings
Number of subjects: 682

Group type: COMPARATOR
Intervention: Control warning (text-only based on FDA-required warnings)
Number of subjects: 682
Study: 23629867

Group type: EXPERIMENTAL
Intervention: Real H-coil rTMS
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham H-coil rTMS
Number of subjects: 25
Study: 21457677

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 234

Group type: COMPARATOR
Intervention: < 25% improvement in YMRS score
Number of subjects: 234

Group type: COMPARATOR
Intervention: < 50% improvement in YMRS score
Number of subjects: 234
Study: 19586218

Group type: EXPERIMENTAL
Intervention: Resource workshop
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control group (no resource workshop)
Number of subjects: 218
Study: 17371886

Group type: EXPERIMENTAL
Intervention: Alendronate, 70 mg once weekly
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 15605615

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 22

Group type: COMPARATOR
Intervention: Timolol maleate 0.5%
Number of subjects: 22
Study: 11732382

Group type: COMPARATOR
Intervention: tenoxicam 40 mg intravenously (i.v.)
Number of subjects: 60

Group type: COMPARATOR
Intervention: tenoxicam 40 mg intramuscularly (i.m.)
Number of subjects: 60

Group type: COMPARATOR
Intervention: piroxicam 40 mg intramuscularly (i.m.)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: placebo
Number of subjects: 60
Study: 9218667

Group type: EXPERIMENTAL
Intervention: Stepped‐care antihypertensive drug therapy (chlorthalidone 12.5-25 mg or matching placebo, atenolol 25-50 mg or matching placebo)
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736

Group type: EXPERIMENTAL
Intervention: Stepped‐care antihypertensive drug therapy (for patients with prior MI)
Number of subjects: 4736
Study: 7970063

Group type: EXPERIMENTAL
Intervention: Thymopentin-TP5 in addition to antibiotic prophylaxis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Antibiotic therapy alone
Number of subjects: 50
Study: 3121487

Group type: EXPERIMENTAL
Intervention: GHRH (50 micrograms i.v.)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: DOM (5 mg/h infusion)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GHRH (50 micrograms i.v.) plus DOM (5 mg/h i.v.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 15
Study: 29974278

Group type: EXPERIMENTAL
Intervention: Combination group (OK + atropine 0.01% ophthalmic solution)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Monotherapy group (OK)
Number of subjects: 40
Study: 27001471

Group type: EXPERIMENTAL
Intervention: Test group (tablet containing 20 mg of lactoferrin, 2.6 mg of lactoperoxidase, and 2.6 mg of glucose oxidase)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (placebo tablet)
Number of subjects: 39
Study: 25461790

Group type: EXPERIMENTAL
Intervention: Self-help CBT-I with telephone support (SHS)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Self-help CBT-I (SH)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Waiting-list (WL)
Number of subjects: 312
Study: 23876539

Group type: EXPERIMENTAL
Intervention: Rectal misoprostol plus perivascular vasopressin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Perivascular vasopressin alone
Number of subjects: 50
Study: 20047707

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18484507

Group type: EXPERIMENTAL
Intervention: PLRA treatment (+1.00D reading addition)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Spherical flipper treatment (+/‐ 1.50D)
Number of subjects: 24
Study: 16556541

Group type: EXPERIMENTAL
Intervention: Three near zero-order controlled-release pseudoephedrine hydrochloride formulations
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Three formulations
Number of subjects: 10
Study: 12968857

Group type: EXPERIMENTAL
Intervention: Medial taping
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Neutral taping
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Lateral taping
Number of subjects: 71

Group type: COMPARATOR
Intervention: Untaped condition
Number of subjects: 71
Study: 10714142

Group type: EXPERIMENTAL
Intervention: Metacognitive tasks (ease of learning judgments, feeling of knowing judgments, judgments of learning, text comprehension monitoring)
Number of subjects: 0
Study: 9178732

Group type: COMPARATOR
Intervention: Zinc therapy for Wilson's disease (5 years or longer)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc therapy for Wilson's disease (1 year)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc therapy for Wilson's disease (up to 15 years)
Number of subjects: 0
Study: 1545850

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 432

Group type: COMPARATOR
Intervention: Intravenous heparin
Number of subjects: 432
Study: 3929328

Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) insufflation
Number of subjects: 151

Group type: COMPARATOR
Intervention: Room air insufflation
Number of subjects: 151
Study: 29232980

Group type: EXPERIMENTAL
Intervention: Aquatic physiotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Land physiotherapy
Number of subjects: 40
Study: 28444995

Group type: EXPERIMENTAL
Intervention: Peripheral artery disease (PAD)
Number of subjects: 3385
Study: 25583364

Group type: EXPERIMENTAL
Intervention: Sertindole (12-20 mg)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Quetiapine (400-600 mg)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 108
Study: 23474283

Group type: EXPERIMENTAL
Intervention: FMPP (fermented milk product with probiotic)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nonfermented milk product (control)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 36
Study: 21879467

Group type: EXPERIMENTAL
Intervention: FRAX® BMI
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: FRAX® BMD
Number of subjects: 1608

Group type: COMPARATOR
Intervention: Previous fractures
Number of subjects: 1608
Study: 18253752

Group type: EXPERIMENTAL
Intervention: Microsatellite markers (specifically 1805A09 (D18S0325i) and 1806D05 (D18S0181i))
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: High-density association mapping with 14 additional microsatellite markers
Number of subjects: 720
Study: 16646293

Group type: EXPERIMENTAL
Intervention: Women with POF
Number of subjects: 30

Group type: COMPARATOR
Intervention: Postmenopausal women (35 subjects)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy fertile women (27 subjects)
Number of subjects: 30
Study: 14503664

Group type: EXPERIMENTAL
Intervention: Intranasal doses of IS-159 (1, 2, 4, and 6 mg) administered twice at an interval of 4 hours
Number of subjects: 17
Study: 10818174

Group type: EXPERIMENTAL
Intervention: High-resolution computed tomography (HRCT)
Number of subjects: 36
Study: 8992089

Group type: EXPERIMENTAL
Intervention: dexpanthenol-containing artificial tears (Siccaprotect)
Number of subjects: 50

Group type: COMPARATOR
Intervention: dexpanthenol-free eye drops
Number of subjects: 50
Study: 1510394

Group type: COMPARATOR
Intervention: Ceftazidime alone
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus vancomycin
Number of subjects: 127
Study: 6418181

Group type: EXPERIMENTAL
Intervention: Slow-release capsule of ketoprofen lysine (160 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional capsules of ketoprofen lysine (Artrosilene®) (160 mg)
Number of subjects: 8
Study: 31081485

Group type: EXPERIMENTAL
Intervention: ParkinSong intervention (weekly dosage)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ParkinSong intervention (monthly dosage)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ParkinSong intervention
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nontreatment control groups
Number of subjects: 75
Study: 30139035

Group type: COMPARATOR
Intervention: Hydromorphone group (H group)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Hydromorphone supplement with dexmedetomidine 1 μg/kg group (D1 group)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Hydromorphone supplement with dexmedetomidine 2 μg/kg group (D2 group)
Number of subjects: 180
Study: 25954844

Group type: EXPERIMENTAL
Intervention: Oral A. montana (Alpine Pharmaceuticals)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 24375070

Group type: EXPERIMENTAL
Intervention: 10 mg loxapine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (positive control)
Number of subjects: 48
Study: 21808284

Group type: EXPERIMENTAL
Intervention: Nasal spray nicotine replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transdermal nicotine replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall treatment (including all interventions)
Number of subjects: 0
Study: 20949341

Group type: EXPERIMENTAL
Intervention: Morphine sulfate and naltrexone hydrochloride extended release capsules taken intact with water under fed conditions
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Morphine sulfate and naltrexone hydrochloride extended release capsules taken intact with water under fasting conditions
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Morphine sulfate and naltrexone hydrochloride extended release capsules sprinkled on apple sauce
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Morphine sulfate and naltrexone hydrochloride extended release capsules under all treatment conditions
Number of subjects: 36
Study: 17619791

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS), beclomethasone dipropionate 250 microg/day
Number of subjects: 85

Group type: COMPARATOR
Intervention: Short-acting beta2 agonists as needed
Number of subjects: 85
Study: 15895834

Group type: EXPERIMENTAL
Intervention: Experimental injection of 0.5 mL of hypertonic (6%) saline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control injection of 0.5 mL isotonic (0.9%) saline
Number of subjects: 12
Study: 11953554

Group type: EXPERIMENTAL
Intervention: Stair climbing
Number of subjects: 46
Study: 11300578

Group type: EXPERIMENTAL
Intervention: Bad news with indefinite consequences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bad news with definite consequences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recipient as a friend
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recipient as a stranger
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moral responsibility to transmit the news
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Good news transmission
Number of subjects: 0
Study: 9202087

Group type: EXPERIMENTAL
Intervention: 10 mg of oral zinc as zinc sulfate, given daily for up to 7 months
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 8434669

Group type: EXPERIMENTAL
Intervention: 48 mg intravenous cocaine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3323274

Group type: EXPERIMENTAL
Intervention: Absorbent gelling material disposable diapers
Number of subjects: 1614

Group type: COMPARATOR
Intervention: Conventional disposable diapers
Number of subjects: 1614

Group type: COMPARATOR
Intervention: Home-laundered cloth diapers
Number of subjects: 1614
Study: 27927036

Group type: EXPERIMENTAL
Intervention: REHACOP cognitive rehabilitation programme
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 42
Study: 26844988

Group type: EXPERIMENTAL
Intervention: Big Data research applications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Development of large, multicenter, and high-quality databases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Big Data research
Number of subjects: 0
Study: 23621170

Group type: EXPERIMENTAL
Intervention: Maintenance of two applications per week (group A)
Number of subjects: 885

Group type: COMPARATOR
Intervention: On-demand therapy (group B)
Number of subjects: 885
Study: 23878826

Group type: EXPERIMENTAL
Intervention: Resin-based (EndoRez)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Glass ionomer-based (Activ GP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional gutta-percha plus pulp sealer (GP/EWT)
Number of subjects: 45
Study: 20080875

Group type: EXPERIMENTAL
Intervention: 18-month weight loss intervention (n = 159, mean weight loss = -4.8 kg)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control group (not randomized to weight loss intervention, n = 159, mean weight loss = -1.4 kg)
Number of subjects: 318
Study: 17678570

Group type: EXPERIMENTAL
Intervention: Soya-based capsules (35 mg isoflavones equivalent aglycone)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Soya-based cheese (35 mg isoflavones equivalent aglycone)
Number of subjects: 12
Study: 15808260

Group type: EXPERIMENTAL
Intervention: Fibrin glue (Beriplast P)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nylon 10-0 suture
Number of subjects: 22
Study: 12959436

Group type: EXPERIMENTAL
Intervention: Anterior temporal lobectomy (ATL)
Number of subjects: 47
Study: 10553821

Group type: EXPERIMENTAL
Intervention: Nicardipine 0.25 mg IV bolus
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nicardipine 0.50 mg IV bolus
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nicardipine 1.00 mg IV bolus
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nicardipine 2.00 mg IV bolus
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nicardipine (all doses)
Number of subjects: 40
Study: 8549180

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2062546

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 10
Study: 29855695

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (group A, immunotherapy arm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy (group B, control arm)
Number of subjects: 0
Study: 26818932

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (group meetings)
Number of subjects: 0
Study: 24434948

Group type: EXPERIMENTAL
Intervention: High-dose oral vitamin A supplementation (5,000 IU vitamin A/kg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21365461

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 5454

Group type: COMPARATOR
Intervention: PPI users
Number of subjects: 5454

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5454
Study: 20860888

Group type: EXPERIMENTAL
Intervention: Antidepressants (SSRIs prescribed by GP)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Listening visits (non-directive counselling)
Number of subjects: 254
Study: 17473917

Group type: EXPERIMENTAL
Intervention: Atacicept (2.1, 70, 210 or 630 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Atacicept (70, 210, 630 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 16358382

Group type: COMPARATOR
Intervention: EEG power in MCI patients at rest
Number of subjects: 35

Group type: COMPARATOR
Intervention: EEG power in MCI patients during working memory tasks
Number of subjects: 35

Group type: COMPARATOR
Intervention: EEG coherence in MCI patients during working memory tasks
Number of subjects: 35

Group type: COMPARATOR
Intervention: EEG coherence in MCI patients at rest
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Correlation analysis of EEG powers and MMSE scores
Number of subjects: 35
Study: 12213868

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa (AN)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study: 9615244

Group type: EXPERIMENTAL
Intervention: Initial pilot campaign exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive campaign exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parents' exposure to comprehensive campaign
Number of subjects: 0
Study: 7647732

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 8 mg/24 h
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2515594

Group type: EXPERIMENTAL
Intervention: Cimetidine tablets 400 mg b.i.d.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cimetidine suspension
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 350346

Group type: EXPERIMENTAL
Intervention: Bromhexine 24 mg/day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bromhexine 48 mg/day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 31791307

Group type: EXPERIMENTAL
Intervention: Abstainers (self-reported 7-day point prevalence abstinence)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Non-abstainers (continued smoking)
Number of subjects: 99
Study: 26911365

Group type: EXPERIMENTAL
Intervention: Half-time stress scans
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Half-time scans
Number of subjects: 80

Group type: COMPARATOR
Intervention: Quarter-time scans
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Reduced radiopharmaceutical activity to 25% of reference
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Reduced radiopharmaceutical activity to 50%
Number of subjects: 80
Study: 25854012

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied to Sanyinjiao (SP 6), Zigong (EX CA 1), Zhongji (CV 3), and Guanyuan (CV 4), treatment given once every two days until egg collection, needles retained for 30 min each time
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 66
Study: 23980846

Group type: EXPERIMENTAL
Intervention: Black currant seed oil (BCSO) supplementation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Atopic dermatitis status of mothers
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Atopic dermatitis status of infants
Number of subjects: 61
Study: 21720656

Group type: EXPERIMENTAL
Intervention: Cetaphil RestoradermTM Moisturizer (CRM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetaphil RestoradermTM Moisturizer (CRM) with topical steroid
Number of subjects: 0
Study: 19246088

Group type: EXPERIMENTAL
Intervention: Kyphoplasty treatment
Number of subjects: 300

Group type: COMPARATOR
Intervention: Non-surgical care
Number of subjects: 300

Group type: COMPARATOR
Intervention: Comparison between kyphoplasty and non-surgical care
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 300
Study: 17467008

Group type: EXPERIMENTAL
Intervention: Standardized antipsychotic treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 20
Study: 15011764

Group type: EXPERIMENTAL
Intervention: Enhanced Care (EC)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 74
Study: 11405347

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surrogate end-points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Central registry of observational trials
Number of subjects: 0
Study: 8989024

Group type: EXPERIMENTAL
Intervention: Propofol at a rate of 1 mg.kg‐1.h‐1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intralipid 0.1 ml.kg‐1.h‐1
Number of subjects: 10
Study: 8480730

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocte plus sucralfate 1 g tds
Number of subjects: 259

Group type: COMPARATOR
Intervention: Ranitidine 300 mg nocte plus placebo
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 259
Study: 3121354

Group type: EXPERIMENTAL
Intervention: 200 micrograms buserelin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline spray (placebo control)
Number of subjects: 24
Study: 31190493

Group type: EXPERIMENTAL
Intervention: Acupuncture at 'reflection points' of the affected side and local acupoints in acute phase, with electroacupuncture in stationary phase and Zusanli (ST 36) in recovery phase.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional acupuncture at Yifeng (TE 17) of the affected side and local acupoints, with electroacupuncture in stationary phase and Zusanli (ST 36) in recovery phase.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ultrashort wave on Yifeng (TE 17) of the affected side, with same treatment as group B in stationary and recovery phases.
Number of subjects: 90
Study: 28161352

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 U
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg (escalated to 10 mg at week 6)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25441247

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: 1:1 Propofol/Ketamine
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: 4:1 Propofol/Ketamine
Number of subjects: 271
Study: 23837269

Group type: EXPERIMENTAL
Intervention: Detailed standard written and verbal instructions
Number of subjects: 108

Group type: COMPARATOR
Intervention: Detailed standard written instructions only
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Operator experience (varied levels)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Patient sex (male/female)
Number of subjects: 108
Study: 21967317

Group type: EXPERIMENTAL
Intervention: IGF‐I treatment (50 μg/kg twice daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study: 19833270

Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 0.375% levobupivacaine
Number of subjects: 73
Study: 16698413

Group type: EXPERIMENTAL
Intervention: Albendazole treatment every 2 months for 12 months (total of 7 treatments)
Number of subjects: 2373

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 2373

Group type: EXPERIMENTAL
Intervention: Albendazole treatment
Number of subjects: 2373